Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by E Fund Management Co. Ltd.

Key Points

• E Fund Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 53.6%, acquiring a total of 4,912 shares valued at approximately $3.1 million as of the latest SEC filing.
• Regeneron Pharmaceuticals reported an EPS of $12.89 for its recent quarter, significantly surpassing the consensus estimate of $8.43, while revenue reached $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, equating to an annual yield of 0.6%, with the dividend payout ratio being 8.87%.

E Fund Management Co. Ltd. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 53.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,912 shares of the biopharmaceutical company's stock after purchasing an additional 1,714 shares during the quarter. E Fund Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $3,115,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares during the period. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $427,000. Sagespring Wealth Partners LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $382,000. CreativeOne Wealth LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $318,000. Finally, Belpointe Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals by 6.9% during the 4th quarter. Belpointe Asset Management LLC now owns 1,970 shares of the biopharmaceutical company's stock valued at $1,403,000 after acquiring an additional 127 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on REGN shares. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group restated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $838.00.

Regeneron Pharmaceuticals Stock Up 0.8%

Regeneron Pharmaceuticals stock traded up $4.42 during trading hours on Thursday, reaching $565.97. The stock had a trading volume of 975,056 shares, compared to its average volume of 986,507. The company has a market cap of $59.99 billion, a price-to-earnings ratio of 14.26, a PEG ratio of 1.90 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business's 50 day moving average price is $542.46 and its 200-day moving average price is $596.26. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.